ArticleFrontiers in microbiology2026
Neutrophil CD64 index for rapid diagnosis of
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Value of CD4+/CD8+ Ratio Combined with nCD64 Index in Bronchoalveolar Lavage Fluid for Differential Diagnosis of Lung Cancer and Non-lung Cancer Diseases].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: This retrospective cohort study (July 2022-March 2025) analyzed mechanically ventilated malignancy patients with unexplained diffuse pulmonary infiltrates at a tertiary intensive care unit (ICU). PJP diagnosis required predefined clinical, radiological, and bronchoalveolar lavage fluid metagenomic next-generation sequencing (BALF mNGS) criteria. The nCD64 index was measured via flow cytometry at ICU admission and serially after ≥3 days of anti-PJP therapy. Diagnostic performance for PJP and prognostic value for 28-day mortality were assessed. Results: Among 28 PJP and 38 non-PJP patients, nCD64 index was significantly higher in PJP (13.33 vs. 2.84, Conclusion: The nCD64 index functions as a dual-purpose biomarker for malignancy patients with respiratory failure requiring mechanical ventilation: it provides a rapid, non-invasive diagnostic tool for PJP and dynamically stratifies mortality risk. Moreover, dynamic tracking offers a real-time window into treatment response, guiding therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.